Repligen (NASDAQ:RGEN) Director Karen A. Dawes sold 20,000 shares of the stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $41.80, for a total transaction of $836,000.00. Following the completion of the transaction, the director now owns 114,957 shares in the company, valued at $4,805,202.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
RGEN stock opened at $41.79 on Wednesday. The company has a market capitalization of $1.84 billion, a PE ratio of 60.57, a PEG ratio of 2.80 and a beta of 0.83. Repligen has a twelve month low of $41.70 and a twelve month high of $42.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 12.22 and a quick ratio of 10.25.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.02. The business had revenue of $44.80 million during the quarter, compared to the consensus estimate of $43.88 million. Repligen had a return on equity of 6.06% and a net margin of 18.48%. The company’s revenue was up 46.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.15 earnings per share. sell-side analysts predict that Repligen will post 0.71 EPS for the current year.
Several brokerages have commented on RGEN. BidaskClub upgraded shares of Repligen from a “hold” rating to a “buy” rating in a research note on Monday. Zacks Investment Research raised Repligen from a “hold” rating to a “buy” rating and set a $42.00 price objective for the company in a report on Thursday, April 26th. Finally, TheStreet raised Repligen from a “c” rating to a “b-” rating in a report on Tuesday, March 13th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Repligen currently has a consensus rating of “Buy” and a consensus price target of $44.25.
Repligen Corporation, a bioprocessing company, focuses on the development, manufacture, and commercialization of products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It manufactures and supplies Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins for use in the downstream purification of monoclonal antibodies; and growth factor products used to supplement cell culture media to increase cell growth and productivity in a bioreactor.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.